Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL251369 | 1.00 | HSD17B10 (0.52) | HSD17B10TDP1TSHRTP53EGLN1 | |
| Maleic Acid SCHEMBL4507841 | 0.97 | HSD17B10 (0.50) | HSD17B10TDP1TSHRTP53EGLN1 | |
| Fumaric Acid SCHEMBL9248586 | 0.97 | HSD17B10 (0.50) | HSD17B10TDP1TSHRTP53EGLN1 | |
| Maleic Acid SCHEMBL10493320 | 0.90 | HSD17B10 (0.70) | HSD17B10TDP1TSHRTP53EGLN1 | |
| SCHEMBL1014778 | 0.87 | HCAR2 (0.52) | HSD17B10TDP1TSHRTP53EGLN1 | |
| SCHEMBL4168638 | 0.87 | HCAR2 (0.52) | HSD17B10TDP1TSHRTP53EGLN1 | |
| Monomethyl Fumarate SCHEMBL7123923 | 0.87 | HCAR2 (0.71) | HSD17B10TDP1TSHRTP53EGLN1 | |
| Maleic Acid SCHEMBL713343 | 0.82 | TSHR (0.64) | HSD17B10TDP1TSHRTP53EGLN1 | |
| Fumaric Acid SCHEMBL713345 | 0.82 | TSHR (0.64) | HSD17B10TDP1TSHRTP53EGLN1 | |
| Maleic Acid SCHEMBL342490 | 0.82 | TSHR (0.64) | HSD17B10TDP1TSHRTP53EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338198-A1 | COMPOSITION FOR TREATING DERMATITIS AND ICHTHYOSIS, AND METHOD FOR TREATING DERMATITIS AND ICHTHYOSIS | SKINVISIBLE PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | claimed |
| US-10292917-B2 | Oral care composition | COLGATE-PALMOLIVE COMPANY (US) | 2019-05-21 | — | — | US | disclosed |
| EP-2934689-B1 | ORAL CARE COMPOSITION | GABA INT HOLDING GMBH (CH) | 2017-09-27 | — | — | EP | disclosed |
| EP-2519215-B1 | ORAL CARE COMPOSITION | COLGATE PALMOLIVE CO (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20150366768-A1 | Oral Care Composition | GABA INTERNATIONAL HOLDING AG (CH) | 2015-12-24 | — | — | US | disclosed |
| EP-2934689-A1 | ORAL CARE COMPOSITION | GABA International Holding AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20140219951-A1 | AMIDO-AMINE DENDRIMER COMPOSITIONS | GENZYME CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014094900-A1 | ORAL CARE COMPOSITION | GABA INTERNATIONAL HOLDING AG (CH) | 2014-06-26 | — | — | WO | disclosed |
| EP-2200566-A1 | IMPROVED TOPICAL PAIN RELIEF PRODUCT | McNeil-PPC, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090098173-A1 | TOPICAL PAIN RELIEF PRODUCT | MCNEIL-PPC, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2009049190-A1 | IMPROVED TOPICAL PAIN RELIEF PRODUCT | MCNEIL-PPC, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-6756059-B2 | PREPARED BY MELT PROCESSING A HYDROPHOBIC POLYMER COMPOSITION THAT INCLUDES REPEATING PYRROLIDONE/ALKYLENE GROUPS CONTAINING AT LEAST 10 CARBON ATOMS, AND A HYDROPHILIC POLYMER COMPOSITION INCLUDING REPEATING CARBOXYLIC OR HYDROXYL GROUPS | SKINVISIBLE PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| EP-0957117-B1 | Continuous process for producing rubbery polymer | ELIOKEM SAS (FR) | 2003-10-08 | — | — | EP | disclosed |
| US-20030044436-A1 | Topical composition, topical composition precursor, and methods for manufacturing and using | SKINVISIBLE PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| US-6077903-A | FIRST PHASE MONOMER SOLUTION CONTAINING BUTYL ACRYLATE, AN ACRYLIC MONOMER, ACRYLONITRILE AND A CROSSLINKING AGENT IS CHARGED INTO AT LEAST THREE INITIAL REACTORS; SECOND PHASE MONOMER SOLUTION CONTAINING STYRENE AND ACRYLONITRILE | THE GOODYEAR TIRE RUBBER COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0957117-A1 | Continuous process for producing rubbery polymer | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338198-A1 | COMPOSITION FOR TREATING DERMATITIS AND ICHTHYOSIS, AND METHOD FOR TREATING DERMATITIS AND ICHTHYOSIS | CUTA, SERPINB1, PRSS1 | HSD17B10 951/4885TDP1 412/4885TSHR 2104/4885 |
| US-20140219951-A1 | AMIDO-AMINE DENDRIMER COMPOSITIONS | PAM, ARGLU1, NAAA | HSD17B10 4694/4885TDP1 4016/4885TSHR 1091/4885 |
| US-20030044436-A1 | Topical composition, topical composition precursor, and methods for manufacturing and using | CUTA, DHPS, TSLP | HSD17B10 107/4885TDP1 224/4885TSHR 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.